Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – The past fortnight delivered the most jam-packed period of meaningful news our sector has seen in 2026. Federal rescheduling hearings opened. Virginia finally locked in its retail framework. Definium posted the cleanest psychedelic clinical data the FDA has ever been handed. Glass House earned a NYSE listing. And California’s midyear market numbers gave operators a cold, clear picture of where things stand. Every one of these developments carries operational and capital implications that will echo well past the summer.

1. The DEA Takes the Stand on Schedule III

The week’s biggest story did not happen on a trading floor. On June 30, the DEA formally opened hearings on reclassifying adult-use Cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). A proceeding is scheduled to run through July 15. The format raised immediate objections. The DEA, serving as proponent of its own rule, granted standing only to parties opposed to reclassification – seven groups including Smart Approaches to Marijuana (SAM). NORML was denied participation. The Cannabis Industry Association raised similar objections. Chief Administrative Law Judge Derek Julius also ruled that proceedings would not be livestreamed, limiting public access to in-person attendance.

The stakes are real and specific. A completed Schedule III rule would not legalize adult-use Cannabis nationally, but it would standardize the regulatory mess and end the application of Section 280E – the tax code provision that bars Cannabis businesses from deducting ordinary expenses. For MSOs currently absorbing effective tax rates that would cripple any other legal industry, 280E relief alone would materially alter cash flow and, in many cases, change the calculus on which operators survive. Running in parallel, the SAFE Banking Act returned to Congress ahead of the DEA hearing, a signal that legislative and regulatory timelines are increasingly synchronized.

2. Virginia Closes a Five-Year Loop

After legalization, a political reversal, a failed retail bill, a governor’s veto, and a compromise struck on June 16, Virginia finally has a Cannabis retail framework. The Virginia General Assembly approved and Governor Abigail Spanberger signed the state budget, creating a legal, regulated adult-use retail Сannabis market. Licensed retailers could open doors July 1, 2027, with applications accepted from February 1. The deal caps retail licenses at 350 statewide, sets a 6% state excise tax rising to 8% in 2029, and allows existing medical operators to convert to dual licenses for a $10 million fee.

3. State-Level Market Development

Regulatory activity across U.S. states was unusually dense. Georgia expanded access to its medical Cannabis program, adding conditions and patients to an approach that basically ran under tight constraints since the passage of the Hope Act.

Nebraska took its first legislative step toward establishing a state-grown medical Cannabis supply, a move that, if executed, would reduce dependence on out-of-state operators and potentially reshape the state’s cost structure.

Delaware moved to formally regulate THC-infused beverages, joining a growing group of states attempting to pull hemp-derived THC products into a controlled framework. Ohio also saw hemp THC beverages return to shelves after last fall’s regulatory disruption.

Sacramento cleared the regulatory path for Cannabis consumption lounges, a signal that California municipalities are willing to push retail formats further even as the licensed market wrestles with margin pressure.

On the enforcement side, California allocated $227 million toward Cannabis enforcement operations, and that figure matters. California’s Department of Cannabis Control estimates that only 40% of Cannabis consumed in the state flows through licensed channels. Enforcement alone won’t fix that split, but sustained pressure on unlicensed operators is a necessary condition for any licensed retailer to see margin improvement.

4. Listings & Capital Markets

Glass House Brands secured NYSE listing approval – a meaningful milestone for a California-based operator that has positioned itself as a low-cost, high-volume cultivator. Getting listed on a major U.S. exchange speaks volumes to investors and opens the door to institutional capital.

California’s licensed market recorded $323.1 million in June sales, pushing H1 2026 to just under $1.95 billion, roughly flat year-over-year, suggesting the market has stabilized near its floor even if structural margin issues persist.

Tilray moved on the corporate development front, acquiring HelloMD to build out its Canadian medical Cannabis patient network.

Ora Pharm completed the Helius acquisition, becoming New Zealand’s largest medical Cannabis company.

High Tide tightened its ownership structure with a new two-part rights plan.

Legal Cannabis generated billions and hit new highs across key states, reinforcing that consumer demand remains intact even in markets under pressure.

On the product and consumer side, AMASS invested in Afterdream, a hemp-derived THC beverage brand, reflecting accelerating institutional interest in the alternative beverage channel.

Splash Beverage Group took a global license on CannEpil, targeting drug-resistant epilepsy (DRE), an indication with documented clinical precedent.

Cannabis retailers continue to face an engagement gap in loyalty programs, a persistent weakness in an industry where customer retention and lifetime value are increasingly critical differentiators.

5. Psychedelics Hit a Clinical Milestone

Definium Therapeutics reported positive topline Phase 3 data from its Emerge study of DT120 [a single-dose, orally disintegrating tablet formulation of pharmaceutical LSD] in adults with major depressive disorder (MDD). Wall Street described the efficacy results as exceeding expectations. MDD affects more than 21 million American adults annually and carries a $326 billion economic cost; fewer than one in three patients achieve remission after first-line treatment. Definium plans to advance toward an FDA submission.

Meanwhile, Helus Pharma reported its APPROACH Phase 3 study has surpassed 88% enrollment for its own MDD candidate, with a topline data readout expected in Q4 2026. Taken together, these two programs represent the clearest indication yet that the psychedelic medicine sector is maturing from preclinical promise to approvable clinical evidence.

Ultimately, Q2 2026 was the quarter that moved psychedelics substantively forward, not as speculative capital raising but as verified clinical development.

HCN Insight

Two forces are converging in ways that will define the next 18 months of business in Cannabis and Psychedelics. The first, in Cannabis, is regulatory normalization and a slow but steady shift in federal and state frameworks. None of it is fast. None of it is guaranteed. But the direction is consistent.

Operators who have managed their balance sheets conservatively, built real revenue, and maintained compliance infrastructure are positioned to capture disproportionate benefit from 280E relief, new state markets, and improved capital access. Those who haven’t are not.

The second force is clinical validation in psychedelics. Definium’s Emerge data is institutional proof, the kind that moves reimbursement committees, FDA reviewers, and large pharma business development teams. The Cannabis sector spent more than a decade proving that restricted substances could carry legitimate commercial and clinical lives outside the Schedule I framework. Psychedelic developers are now compressing that timeline through the FDA’s standard approval channel. The capital that follows proven Phase 3 data is categorically different from early-stage venture capital.

Both industries are entering a phase where execution discipline, regulatory competency, and financial staying power matter more than market narrative. The companies that understand that distinction are the ones worth watching.